Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by JLGeminion Mar 03, 2011 11:20am

296 Views

Post# 18225168

Hold & Buy Headwinds

It appears my posts warning retail investors of a buy side manipulation are having an effect. The buy side manipulation is having a difficult time with the resistance to it. In 2009, readers became aware of the manipulation and trading volumes dropped. The 2009 correction rally was evidence of the buy side manipulation was experiencing headwinds. Retail investors holding onto their shares create the problem of no supply to buy. The reaction to recent posts to retail investors to buy and use margin is causing more headwinds as evidence to the posts against buying Oncolytics.

Retail investors do not be deceived by the ongoing buy side manipulation of ONCY and ONC. Institutional investors are taking control of Oncolytics by buying your shares at their lowest cost. Existing and potential retail investors do your due diligence on Oncolytics. Do you see a partnership deal by mid year like the analysts at RBC Capital Markets? They modeled Oncolytics share price in 2016 at $26.52 and qualified it as being conservative. Read the post of my detractors. They reflect the collective voice supporting the buy side manipulation. They want you to sell. They last thing that they want is for you to buy. Their attacks on me and the concept of a buy side manipulation are endorsements to hold and buy. Like a magic trick, the magic disappears if the trick is revealed. They can not be honest and say that they want to buy your shares at the lowest price. I can honestly say that I post to warn retail investors. The financial gain to me in posting is to buy more shares on margin. The number of additional shares is marginal compared to my existing holdings. The major portion of my holdings was purchased when the buy side manipulation had depressed to the low $2.00 range and below. I was not fooled by it and dirty tricks were not being played at that time.

Do your due diligence and see history repeat itself. The following is a table of the closing numbers of Dendreon, DNDN, on the NASDAQ for the month of April 2009. Prior to April 2009 the stock price of DNDN was flat lining at $5.00. Were institutional investors surprised by the movement in DNDN in April or retail investors?

Date	Closing Price	Volume
1-Apr-09	$4.14	3,199,650
2-Apr-09	4.34	2,427,867
3-Apr-09	5.99	22,497,200
6-Apr-09	6.58	19,585,750
7-Apr-09	6.58	7,346,062
8-Apr-09	6.37	5,392,639
9-Apr-09	6.30	4,234,697
13-Apr-09	7.30	12,775,310
14-Apr-09	16.99	65,120,890
15-Apr-09	17.17	19,294,060
16-Apr-09	17.03	6,894,881
17-Apr-09	17.99	17,799,470
20-Apr-09	19.52	17,724,250
21-Apr-09	19.74	11,008,510
22-Apr-09	20.12	7,358,435
23-Apr-09	20.33	6,123,418
24-Apr-09	20.08	7,393,327
27-Apr-09	21.55	18,569,850
28-Apr-09	11.81	28,070,740
29-Apr-09	22.94	48,235,790
30-Apr-09	21.20	17,468,950
Yesterday
2-Mar-11	$33.48	3,353,123